These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. A Brief Historical Overview of Psychedelic Research. Geyer MA Biol Psychiatry Cogn Neurosci Neuroimaging; 2024 May; 9(5):464-471. PubMed ID: 38000715 [TBL] [Abstract][Full Text] [Related]
8. Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives. Pallavicini C; Vilas MG; Villarreal M; Zamberlan F; Muthukumaraswamy S; Nutt D; Carhart-Harris R; Tagliazucchi E Neuroimage; 2019 Oct; 200():281-291. PubMed ID: 31247301 [TBL] [Abstract][Full Text] [Related]
9. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders. De Gregorio D; Enns JP; Nuñez NA; Posa L; Gobbi G Prog Brain Res; 2018; 242():69-96. PubMed ID: 30471683 [TBL] [Abstract][Full Text] [Related]
10. Psychedelics and mental health: a population study. Krebs TS; Johansen PØ PLoS One; 2013; 8(8):e63972. PubMed ID: 23976938 [TBL] [Abstract][Full Text] [Related]
11. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078 [TBL] [Abstract][Full Text] [Related]
12. Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness. Forstmann M; Kettner HS; Sagioglou C; Irvine A; Gandy S; Carhart-Harris RL; Luke D J Psychopharmacol; 2023 Jan; 37(1):93-106. PubMed ID: 36601974 [TBL] [Abstract][Full Text] [Related]
13. Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action. Canal CE Handb Exp Pharmacol; 2018; 252():227-260. PubMed ID: 29532180 [TBL] [Abstract][Full Text] [Related]
14. Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution. Tagliazucchi E; Roseman L; Kaelen M; Orban C; Muthukumaraswamy SD; Murphy K; Laufs H; Leech R; McGonigle J; Crossley N; Bullmore E; Williams T; Bolstridge M; Feilding A; Nutt DJ; Carhart-Harris R Curr Biol; 2016 Apr; 26(8):1043-50. PubMed ID: 27085214 [TBL] [Abstract][Full Text] [Related]
15. Psilocybin and Other Classic Psychedelics in Depression. Nutt DJ; Peill JM; Weiss B; Godfrey K; Carhart-Harris RL; Erritzoe D Curr Top Behav Neurosci; 2024; 66():149-174. PubMed ID: 37955822 [TBL] [Abstract][Full Text] [Related]
16. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner. Lyvers M; Meester M J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892 [TBL] [Abstract][Full Text] [Related]
17. Addressing the Current Knowledge and Gaps in Research Surrounding Lysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in Rodent Models. Ezeaka UC; Kim HJJ; Laprairie RB Curr Top Med Chem; 2023; 23(23):2232-2241. PubMed ID: 37409550 [TBL] [Abstract][Full Text] [Related]